LEADER 01826oam  2200421I  450 
001 9910706173103321
005 20170913092611.0
035   $a(CKB)5470000002454694
035   $a(OCoLC)1001810997
035   $a(OCoLC)995470000002454694
035   $a(EXLCZ)995470000002454694
100   $a20170824d2017      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug control policy, information on status of federal efforts and key issues for preventing illicit drug use: testimony before the Committee on Oversight and Government Reform, House of Representatives /$fstatement of Diana Maurer
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2017.
215   $a1 online resource (15 pages) $ccolor illustrations
225 1 $aTestimony ;$vGAO-17-766T
300   $a"For release ... July 26, 2017."
320   $aIncludes bibliographical references.
517   $aDrug control policy, information on status of federal efforts and key issues for preventing illicit drug use
606   $aDrug control$zUnited States$xEvaluation
606   $aDrug abuse$xGovernment policy$zUnited States
615  0$aDrug control$xEvaluation.
615  0$aDrug abuse$xGovernment policy
702   $aMaurer$b Diana
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Oversight and Government Reform,
801  0$bGPO
801  1$bGPO
801  2$bMERUC
801  2$bGPO
906   $aBOOK
912   $a9910706173103321
996   $aDrug control policy, information on status of federal efforts and key issues for preventing illicit drug use: testimony before the Committee on Oversight and Government Reform, House of Representatives$93281897
997   $aUNINA